190 related articles for article (PubMed ID: 29218740)
1. Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration.
Green DJ; Liu XI; Hua T; Burnham JM; Schuck R; Pacanowski M; Yao L; McCune SK; Burckart GJ; Zineh I
Clin Pharmacol Ther; 2018 Nov; 104(5):983-988. PubMed ID: 29218740
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
[TBL] [Abstract][Full Text] [Related]
3. Adaptive enrichment designs for confirmatory trials.
Lai TL; Lavori PW; Tsang KW
Stat Med; 2019 Feb; 38(4):613-624. PubMed ID: 30277591
[TBL] [Abstract][Full Text] [Related]
4. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
5. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
6. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
[TBL] [Abstract][Full Text] [Related]
7. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
8. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
Rowe-Rendleman CL
Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
[TBL] [Abstract][Full Text] [Related]
9. Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA.
Green DJ; Burnham JM; Schuette P; Liu XI; Maas BM; Yao L; McCune SK; Chen J; van den Anker JN; Burckart GJ
J Clin Pharmacol; 2018 Jul; 58(7):885-890. PubMed ID: 29663424
[TBL] [Abstract][Full Text] [Related]
10. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
[TBL] [Abstract][Full Text] [Related]
12. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
[TBL] [Abstract][Full Text] [Related]
13. Success rates for US and Canadian anticancer drug development efforts in pediatric oncology.
Oliviero E; Kourkopoulos G; Kimmelman J
Pediatr Blood Cancer; 2022 Aug; 69(8):e29534. PubMed ID: 35739610
[TBL] [Abstract][Full Text] [Related]
14. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.
Powers JH; Ross DB; Brittain E; Albrecht R; Goldberger MJ
Clin Infect Dis; 2002 Mar; 34(6):879-81. PubMed ID: 11850875
[No Abstract] [Full Text] [Related]
15. A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations.
Babiker HM; Davis L; Larson K; Placencia C; Swensen C; Tenneti P; Lim M; Cañamar R; Curtis J; Castillo E; Mancuso J; Rensvold D; Martinez S; Macias L; Recio-Boiles A; Chandana SR; Mahadevan D
Expert Opin Investig Drugs; 2019 Aug; 28(8):675-686. PubMed ID: 31327293
[No Abstract] [Full Text] [Related]
16. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
17. Flexibility in the FDA approach to orphan drug development.
Hunter NL; Rao GR; Sherman RE
Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
[No Abstract] [Full Text] [Related]
18. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
[No Abstract] [Full Text] [Related]
19. Evaluating the Use of KIM-1 in Drug Development and Research Following FDA Qualification.
Chen R; Sanyal S; Thompson A; Ix JH; Haskins K; Muldowney L; Amur S
Clin Pharmacol Ther; 2018 Dec; 104(6):1175-1181. PubMed ID: 29761868
[TBL] [Abstract][Full Text] [Related]
20. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.
Wharton GT; Murphy MD; Avant D; Goldsmith JV; Chai G; Rodriguez WJ; Eisenstein EL
Pediatrics; 2014 Aug; 134(2):e512-8. PubMed ID: 25022732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
